Save 10% off on your first order with coupon code: PANDA10

Health & Wellness Blog

27Feb, 2026

Saxenda vs Mounjaro: Mounjaro 22.5% Loss vs Saxenda 8% – Head-to-Head Analysis

February 27, 2026|

Mounjaro dominates Saxenda across every major metric: 22.5% body weight loss vs 8%, once-weekly injection vs daily injection, and dual GLP-1/GIP mechanism vs single GLP-1. Both Saxenda and Mounjaro are prescription medications designed to support weight management by reducing appetite and helping patients lose weight when combined with lifestyle changes. However, clinical trial data shows [...]

21Feb, 2026

Rybelsus vs Januvia: Oral GLP-1 vs DPP4 Comparison (Weight Loss, A1C, Cost)

February 21, 2026|

Rybelsus and Januvia are two widely prescribed oral medications for adults with type 2 diabetes, but they belong to fundamentally different drug classes.  Rybelsus (oral semaglutide), manufactured by Novo Nordisk, is a GLP-1 receptor agonist the first of its kind available as an oral tablet rather than an injection.  Januvia (sitagliptin), produced by Merck, is [...]

21Feb, 2026

Trulicity Cost: $987 Monthly Without Insurance + Savings Guide

February 21, 2026|

Trulicity is a brand-name GLP-1 receptor agonist manufactured by Eli Lilly and prescribed primarily for managing type 2 diabetes. Because no generic version exists, out-of-pocket expenses can be steep. The cost of Trulicity depends on a few factors: your insurance plan, dosage, pharmacy location, and whether you qualify for manufacturer savings programs or patient assistance [...]

21Feb, 2026

Rybelsus vs Metformin: Oral GLP-1 vs Biguanide Comparison (Weight Loss, A1C, Cost)

February 21, 2026|

Rybelsus and metformin are both prescription medications used to lower blood sugar levels in adults with type 2 diabetes, but these two diabetes medications work differently and belong to separate drug classes. Rybelsus is a brand-name oral GLP-1 receptor agonist containing the active ingredient semaglutide. It works by mimicking the hormone GLP-1 to increase insulin [...]

20Feb, 2026

Farxiga vs Ozempic: SGLT2 vs GLP-1 Comparison (Weight Loss, A1C, Cost)

February 20, 2026|

Dapagliflozin (Farxiga) and semaglutide (Ozempic) are both medications used to treat type 2 diabetes, yet they work through entirely different pharmacological pathways.  Farxiga is an SGLT2 inhibitor an oral medication that lowers blood glucose levels by blocking glucose reabsorption in the kidneys, causing sugar to be eliminated through urine.  Ozempic is a GLP-1 receptor agonist [...]

20Feb, 2026

Saxenda Cost 2026: $1,349 Monthly Without Insurance + $25 Savings Guide

February 20, 2026|

The list price for Saxenda (liraglutide) is $1,349.02 for a 30-day supply, which includes five 3mL prefilled injectable pens. Saxenda is an FDA-approved GLP-1 receptor agonist prescription medication designed to help adults with obesity or overweight with weight-related medical conditions lose weight and maintain weight loss when used with a reduced calorie diet and increased [...]

20Feb, 2026

Trulicity Coupon 2026: $25 Savings Card, Copay, Discounts Guide

February 20, 2026|

As of early 2026, the average retail price of Trulicity without insurance is approximately $1,395.75 for four Trulicity pens a standard 30-day supply. The good news: several savings programs exist to help eligible patients dramatically reduce what they pay out [...]

17Feb, 2026

Zepbound Insurance Coverage: Complete Guide to Prior Authorization & Approval

February 17, 2026|

Zepbound insurance coverage stands at approximately 45% for commercial plans requiring BMI ≥30 or ≥27 with comorbidities, while Medicare excludes weight-loss indications entirely. Employer-sponsored plans show 55% approval rates after prior authorization. Roughly 97 million Americans are in plans that [...]

13Feb, 2026

Mounjaro Dosage: Complete 2.5mg→15mg Titration Chart + Missed Dose Protocol

February 13, 2026|

Mounjaro (tirzepatide) is an FDA-approved once-weekly injectable medicine manufactured by Eli Lilly for adults and children aged 10 years and older with type 2 diabetes. The active ingredient tirzepatide is a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) [...]

6Feb, 2026

Does Mounjaro Make You Tired? 8-12% Fatigue Rate + Evidence-Based Recovery

February 6, 2026|

Mounjaro (tirzepatide) is an FDA-approved medication to treat type 2 diabetes and support weight loss by mimicking two naturally occurring hormones: glucose-dependent insulinotropic polypeptide (GIP) and GLP-1. These hormones work by enhancing insulin secretion, reducing appetite, slowing gastric emptying, and [...]

5Feb, 2026

Trulicity vs Wegovy: Wegovy 15% Weight Loss vs Trulicity 7 lbs – Diabetes vs Obesity Drugs

February 5, 2026|

Wegovy delivers approximately 15% body weight loss in clinical trials-dramatically outperforming Trulicity’s average weight reduction of about 7–10 lbs (3–5% of body weight). Both are GLP-1 receptor agonists administered as once-weekly injections, yet Wegovy produces roughly 2.5 times greater weight [...]

1Sep, 2025

Ozempic vs Insulin

September 1, 2025|

Effective blood glucose management is a critical need for many. Ozempic and insulin are two commonly used diabetes medications. While both address diabetes, they function differently. Ozempic is a prescription medication for adults with type 2 diabetes. Interestingly, it also [...]

4Aug, 2025

Is Compounded Mounjaro Safe? Understanding Tirzepatide Compounding for Informed Choices

August 4, 2025|

Tirzepatide is a prescription drug that has been gaining popularity. Millions are exploring it for weight management and diabetes. But sometimes, the exact medication isn't readily available. This leads to "compounding."  What are Compounded Drugs? Compounded versions of medications are [...]

3Jun, 2025

Does Ozempic Cause Hair Loss?

June 3, 2025|

You've scrolled through social media, seen the news, and maybe even heard friends talking about Ozempic and its remarkable weight loss results. It's become a household name, but with its growing popularity comes a wave of questions, especially regarding potential [...]

Go to Top
X